Apollo Hospitals Q4 Results: Profit Surges 36% YoY to ₹529 Crore, Revenue Up 18%; ₹10 Dividend Declared - Earnings Sentiment Score

Live News

Apollo Hospitals Q4 Results: Profit Surges 36% YoY to ₹529 Crore, Revenue Up 18%; ₹10 Dividend Declared{随机描述}- Profit growth: Consolidated PAT rose 36% YoY to ₹529 crore, indicating improved profitability despite cost inflation pressures in the healthcare sector. - Revenue expansion: Total income increased 18% to ₹6,605 crore, supported by higher patient footfalls, better payor mix, and robust ancillary services. - EBITDA improvement: EBITDA grew 31% to ₹1,011 crore, with margins expanding to around 15.3%, suggesting enhanced operational efficiency. - Dividend declared: The board proposed a ₹10 per share dividend, reflecting confidence in the company’s cash flow generation and long-term outlook. - Segment strength: The hospital division remained the primary growth driver, while the pharmacy and diagnostics businesses also recorded double-digit revenue gains. - Sector context: India’s healthcare industry is experiencing structural tailwinds, including rising health awareness, medical tourism, and government initiatives like Ayushman Bharat. Apollo’s results align with these broader trends. Apollo Hospitals Q4 Results: Profit Surges 36% YoY to ₹529 Crore, Revenue Up 18%; ₹10 Dividend Declared{随机描述}{随机描述}Apollo Hospitals Q4 Results: Profit Surges 36% YoY to ₹529 Crore, Revenue Up 18%; ₹10 Dividend Declared{随机描述}

Key Highlights

Apollo Hospitals Q4 Results: Profit Surges 36% YoY to ₹529 Crore, Revenue Up 18%; ₹10 Dividend Declared{随机描述}Apollo Hospitals has released its financial results for the fourth quarter of fiscal year 2025-26 (Q4 FY26), showcasing solid growth across key metrics. Consolidated net profit surged 36% compared to the same period last year, reaching ₹529 crore. Revenue from operations grew 18% to ₹6,605 crore, reflecting sustained momentum in patient volumes and higher average revenue per bed. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) rose 31% year-on-year to ₹1,011 crore, with margins improving on better operating leverage and cost efficiencies. The company’s board has recommended a final dividend of ₹10 per equity share of face value ₹5 each, subject to shareholder approval. Management attributed the performance to strong growth in the core hospital business, which benefited from increased occupancy, higher ARPOB (average revenue per occupied bed), and a favourable case mix. The Apollo pharmacy and diagnostics divisions also contributed significantly to the top line, driven by expanded reach and higher prescription volumes. The results come at a time when India’s healthcare sector continues to see strong demand from medical tourism, rising insurance penetration, and increased spending on preventive healthcare. Apollo Hospitals, as one of the largest healthcare chains in the country, remains a key player in that trend. Apollo Hospitals Q4 Results: Profit Surges 36% YoY to ₹529 Crore, Revenue Up 18%; ₹10 Dividend Declared{随机描述}{随机描述}Apollo Hospitals Q4 Results: Profit Surges 36% YoY to ₹529 Crore, Revenue Up 18%; ₹10 Dividend Declared{随机描述}

Expert Insights

Apollo Hospitals Q4 Results: Profit Surges 36% YoY to ₹529 Crore, Revenue Up 18%; ₹10 Dividend Declared{随机描述}The strong quarterly performance from Apollo Hospitals suggests that India’s leading healthcare providers are benefiting from a post-pandemic recovery in elective procedures and international patient inflows. The 36% YoY jump in net profit, coupled with a 31% rise in EBITDA, indicates that the company is successfully navigating input cost inflation through pricing power and scale efficiencies. The declared dividend of ₹10 per share may be seen by market participants as a signal of management’s confidence in sustaining earnings momentum. However, investors should note that past dividend declarations do not guarantee future payouts, and any forward-looking assessments must account for potential regulatory changes, competition, and macroeconomic uncertainties. From a sector perspective, Apollo’s results could bode well for other large hospital chains, as they often serve as a bellwether for the industry. The improving margin profile may also attract attention from analysts tracking the healthcare space, although individual company valuations will depend on factors such as debt levels, expansion plans, and regulatory compliance. Overall, the Q4 FY26 numbers reinforce Apollo Hospitals’ position as a key player in India’s formal healthcare ecosystem, but the stock’s future trajectory would likely be influenced by broader market conditions, including interest rate movements and global risk appetite. No specific price targets or buy/sell recommendations are implied by this report. Apollo Hospitals Q4 Results: Profit Surges 36% YoY to ₹529 Crore, Revenue Up 18%; ₹10 Dividend Declared{随机描述}{随机描述}Apollo Hospitals Q4 Results: Profit Surges 36% YoY to ₹529 Crore, Revenue Up 18%; ₹10 Dividend Declared{随机描述}